When Nausea on Zepbound (tirzepatide) Becomes a Reason to Stop

What the Zepbound label says about stopping

If a maintenance dose is not tolerated, the Zepbound label says to consider a lower maintenance dose [1]. Alongside that, the prescribing information gives a short list of specific instructions:

• Zepbound is not recommended in patients with severe gastroparesis [1].
• The label says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion, especially during dosage initiation and escalation [1].
• If pancreatitis is suspected, the label says to discontinue Zepbound and initiate appropriate management [1].

How common nausea is on Zepbound, and when it happens

The label pools two placebo-controlled trials, SURMOUNT-1 and SURMOUNT-2, in adults with obesity or overweight, with or without type 2 diabetes, treated for up to 72 weeks. That pool included 958 patients on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [1].

Nausea was reported by 8% on placebo, 25% on 5 mg, 29% on 10 mg and 28% on 15 mg [1]. Diarrhea was 8%, 19%, 21% and 23% respectively; vomiting 2%, 8%, 11% and 13%; constipation 5%, 17%, 14% and 11% [1]. Counting any gastrointestinal adverse reaction, 56% of patients on each Zepbound dose reported one, against 30% on placebo [1].

The label also states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1]. Separately, the label notes that tirzepatide delays gastric emptying, that this delay is largest after the first dose and that it diminishes over time [1].

What actually led people to stop in the trials

Stopping the drug was uncommon. In the same pooled trials, 3.4% of placebo patients discontinued for any adverse reaction, compared with 4.8% on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg [1]. Discontinuation specifically for gastrointestinal adverse reactions was 0.5% on placebo versus 1.9%, 3.3% and 4.3% at the three doses; the label reports gastrointestinal reactions as a group and does not break out nausea alone [1].

Severe gastrointestinal adverse reactions were reported by 1% of placebo patients and by 1.7%, 2.5% and 3.1% of patients on 5, 10 and 15 mg [1]. The label adds that the majority of patients who discontinued Zepbound because of adverse reactions did so during the first few months of treatment, and that the reason was gastrointestinal adverse reactions [1].

These are group averages from trials with scheduled dose increases, not a personal threshold.

Symptoms that are not just nausea

The label treats several problems as separate from ordinary nausea and gives specific instructions for each:

• Suspected pancreatitis. The label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Zepbound if pancreatitis is suspected [1]. In the weight-management pool, adjudication-confirmed acute pancreatitis occurred in 0.2% of Zepbound patients and 0.2% of placebo patients [1].
• Raised pancreatic enzymes without symptoms. Mean amylase rose 20% to 25% and mean lipase 28% to 35% on tirzepatide, and the label states the clinical significance of these increases is unknown without signs of pancreatitis [1].
• Gallbladder disease. Cholecystitis was reported in 0.7% of Zepbound patients versus 0.2% on placebo, and cholelithiasis in 1.1% versus 1% [1].
• Dehydration and kidney injury. The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, with the majority of reported events in patients who had gastrointestinal reactions leading to dehydration, and instructs monitoring of renal function in patients reporting reactions that could lead to volume depletion [1].

A lower dose before stopping

If a maintenance dose is not tolerated, the Zepbound label says to consider a lower maintenance dose [1]. Zepbound starts at 2.5 mg once weekly for 4 weeks, and that 2.5 mg dose is for initiation only, not approved as a maintenance dose [1]. Recommended maintenance doses are 5 mg, 10 mg or 15 mg weekly, with increases of 2.5 mg no sooner than every 4 weeks, and the label says to consider treatment response and tolerability when choosing the maintenance dose [1].

If Zepbound is stopped

The label gives tirzepatide a half-life of about 5 days and steady state after 4 weeks of weekly dosing [1]. Weight regain is documented. In SURMOUNT-4, 783 adults received open-label tirzepatide for 36 weeks and 670 were then randomized; from week 36 to week 88, weight changed by -5.5% in those who continued tirzepatide and +14.0% in those switched to placebo, a difference of 19.4 percentage points [2]. That trial tested randomized withdrawal, not stopping because of nausea.